IOVANCE BIOTHERAPEUTICS, INC. — Net Income by Fiscal Year
18 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/0589bc62-da31-4a71-b44e-5043d042f1b3/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-391.0M | 2025-01-01 – 2025-12-31 | evidence 0001104659-26-044958 |
| FY 2024 | $-372.2M | 2024-01-01 – 2024-12-31 | evidence 0001104659-26-044958 |
| FY 2023 | $-444.0M | 2023-01-01 – 2023-12-31 | evidence 0001104659-26-044958 |
| FY 2022 | $-395.9M | 2022-01-01 – 2022-12-31 | evidence 0001104659-26-044958 |
| FY 2021 | $-342.3M | 2021-01-01 – 2021-12-31 | evidence 0001104659-26-044958 |
| FY 2020 | $-259.6M | 2020-01-01 – 2020-12-31 | evidence 0001558370-21-001858 |
| FY 2019 | $-197.6M | 2019-01-01 – 2019-12-31 | evidence 0001104659-20-024830 |
| FY 2018 | $-123.6M | 2018-01-01 – 2018-12-31 | evidence 0001144204-19-010702 |
| FY 2017 | $-92.1M | 2017-01-01 – 2017-12-31 | evidence 0001144204-18-014151 |
| FY 2016 | $-52.9M | 2016-01-01 – 2016-12-31 | evidence 0001144204-17-013535 |
| FY 2015 | $-27.7M | 2015-01-01 – 2015-12-31 | evidence 0001144204-16-087506 |
| FY 2014 | $-12.0M | 2014-01-01 – 2014-12-31 | evidence 0001144204-16-087506 |
| FY 2013 | $-58.3M | 2007-09-17 – 2014-03-31 | evidence 0001354488-14-002559 |
| FY 2012 | $-31.7M | 2007-09-17 – 2013-03-31 | evidence 0001513160-13-000061 |
| FY 2011 | $-33.1M | 2007-09-17 – 2012-03-31 | evidence 0001513160-12-000038 |
| FY 2010 | $-1.6M | 2010-01-01 – 2010-12-31 | evidence 0001144204-12-018611 |
| FY 2009 | $-15.8k | 2009-01-01 – 2009-12-31 | evidence 0001144204-12-018611 |
| FY 2008 | $-58.7k | 2007-09-17 – 2008-12-31 | evidence 0001513160-14-000023 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
IOVANCE BIOTHERAPEUTICS, INC. — all facts · Revenue · Operating Income